Patient Name	
Date of CASGEVY infusion	
CASGEVY Patient ID number	

CASGEVY Treating Physician Name	
CASGEVY Treating Physician Contact Information	
CASGEVY Treating Physician Contact Information After Hours	

CASGEVY word mark and design are registered trademarks of Vertex Pharmaceuticals Incorporated

VERTEX

Patient Alert Card

Important information regarding CASGEVY® ▼ (exagamglogene autotemcel)

Carry this card with you at all times (duplicates or pictures kept on your smart device are recommended). Show it to any doctor who sees you and when you go to any hospital or healthcare clinic.

Tell any healthcare provider who sees you that you have been treated with CASGEVY (exagamglogene autotemcel).

As you have been treated with CASGEVY, you should never donate blood, organs, tissues or cells.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. If you experience any side effects after your treatment with CASGEVY, talk to your doctor or nurse. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk/.

Approved by MHRA November 2026
XB-70-2300001
Date of Preparation: November 2026

casgevy▼ (exagamglogene autotemcel)

Information on Side Effects

Make sure you have all your blood tests as ordered by your doctor.

Call your doctor or nurse right away if you experience any symptoms of bleeding:

- Severe headache
- Abnormal bruising
- Prolonged bleeding
- Bleeding without injury such as:
  - Nosebleeds
  - Bleeding from gums
  - Blood in urine, stool or vomit
  - Coughing up blood

Healthcare Provider Information

- This patient has received CASGEVY (exagamglogene autotemcel) infusion. The infusion was preceded by the administration of a fully myeloablative conditioning agent.
- **The patient is at risk of bleeding due to the possibility of a prolonged period of thrombocytopenia prior to platelet engraftment.**
- Please contact the patient's treating physician listed on the back of this card for further information.
- For more information, refer to the CASGEVY Summary of Product Characteristics, which can be found on https://products.mhra.gov.uk and https://www.medicines.org.uk/emc.
- Report any suspected adverse reactions to CASGEVY (see reporting information on the front page).
- Any suspected adverse reactions to CASGEVY should also be reported to Vertex Pharmaceuticals (Europe) Limited on +44 (0) 800-028-2616 or vertexmedicalinfo@vrtx.com.